CADL vs. QBTS

In the year-to-date period, CADL achieves a 33.99% return, which is significantly higher than QBTS's -13.69% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Candel Therapeutics, Inc. (CADL) and DPCM Capital Inc (QBTS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CADL Sharpe Ratio is 1.83, which is comparable to the QBTS Sharpe Ratio of 1.66. The chart below compares the historical Sharpe Ratios of CADL and QBTS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CADL nor QBTS has paid dividends to shareholders.

The maximum CADL drawdown since its inception was -94.33%, roughly equal to the maximum QBTS drawdown of -96.67%. Use the drawdown chart below to compare losses from any high point for CADL and QBTS. For additional features, visit the drawdowns tool.

The current volatility for Candel Therapeutics, Inc. (CADL) is 24.74%, while DPCM Capital Inc (QBTS) has a volatility of 28.54%. This indicates that CADL experiences smaller price fluctuations and is considered to be less risky than QBTS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Candel Therapeutics, Inc. and DPCM Capital Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.